ReShape Lifesciences prices $3.0M public offering at $0.33/unit; warrants amended

Vyome Holdings, Inc

Offering of 9.1M units at $0.33/unit; each unit: 1 share (or pre-funded warrant) + 1.5 warrants exercisable at $0.33.
Net proceeds ~$2.8M; expected use: Lap-Band marketing, ReShapeCare development, working capital.
Existing warrants for ~1.35M shares amended to $0.33 exercise price upon closing.
Closing expected Oct 3, 2023; Maxim Group sole placement agent with 7% fee plus placement agent warrants.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Vyome Holdings, Inc entered into Securities Purchase Agreement with certain investors valued at approximately $2.8 million (effective 2023-09-29).

Action: entry
Agreement: equity purchase
Counterparty: certain investors
Value: approximately $2.8 million
Effective: 2023-09-29

Exact text from the filing

On September 29, 2023, ReShape Lifesciences Inc. (the "Company") entered into a Securities Purchase Agreement (the "Purchase Agreement") with certain investors (the "Investors")

View on SEC.gov

Browse all material agreements →

Vyome Holdings, Inc filing history →

Source: SEC EDGAR

accession 0001104659-23-107164

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.